;PMID: 10206490
;source_file_1304.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..31] = [t:0..31]
;1)sentence:[e:36..145] = [t:36..145]
;2)section:[e:149..234] = [t:149..234]
;3)section:[e:238..311] = [t:238..311]
;4)sentence:[e:315..453] = [t:315..453]
;5)sentence:[e:454..767] = [t:454..767]
;6)sentence:[e:768..919] = [t:768..919]
;7)sentence:[e:920..1031] = [t:920..1031]
;8)sentence:[e:1033..1126] = [t:1033..1126]
;9)sentence:[e:1127..1303] = [t:1127..1303]
;10)sentence:[e:1304..1426] = [t:1304..1426]
;11)sentence:[e:1428..1539] = [t:1428..1539]
;12)sentence:[e:1540..1672] = [t:1540..1672]
;13)sentence:[e:1673..1791] = [t:1673..1791]
;14)section:[e:1795..1840] = [t:1795..1840]

;section 0 Span:0..31
;Pancreas  1999 Apr;18(3):308-15
(SEC
  (FRAG (IN:[0..8] Pancreas) (CD:[10..14] 1999) (CD:[15..21] Apr;18)
        (-LRB-:[21..22] -LRB-) (CD:[22..23] 3) (-RRB-:[23..24] -RRB-)
        (::[24..25] :) (CD:[25..31] 308-15)))

;sentence 1 Span:36..145
;Immunohistochemical and molecular analysis of giant cell carcinoma of the 
;pancreas: a report of three cases.
;[82..119]:malignancy-type:"giant cell carcinoma of the  pancreas"
(SENT
  (NP-HLN
    (NP
      (NP
        (NP (JJ:[36..55] Immunohistochemical)
          (NML-1 (-NONE-:[55..55] *P*)))
        (CC:[56..59] and)
        (NP (JJ:[60..69] molecular)
          (NML-1 (NN:[70..78] analysis))))
      (PP (IN:[79..81] of)
        (NP
          (NP
            (NML (JJ:[82..87] giant) (NN:[88..92] cell))
            (NN:[93..102] carcinoma))
          (PP (IN:[103..105] of)
            (NP (DT:[106..109] the) (NN:[111..119] pancreas))))))
    (::[119..120] :)
    (NP
      (NP (DT:[121..122] a) (NN:[123..129] report))
      (PP (IN:[130..132] of)
        (NP (CD:[133..138] three) (NNS:[139..144] cases))))
    (.:[144..145] .)))

;section 2 Span:149..234
;Imai Y, Morishita S, Ikeda Y, Toyoda M, Ashizawa T, Yamamoto K, Inoue T, 
;Ishikawa T.
(SEC
  (FRAG (NNP:[149..153] Imai) (NNP:[154..155] Y) (,:[155..156] ,)
        (NNP:[157..166] Morishita) (NNP:[167..168] S) (,:[168..169] ,)
        (NNP:[170..175] Ikeda) (NNP:[176..177] Y) (,:[177..178] ,)
        (NNP:[179..185] Toyoda) (NNP:[186..188] M,) (NNP:[189..197] Ashizawa)
        (NNP:[198..199] T) (,:[199..200] ,) (NNP:[201..209] Yamamoto)
        (NNP:[210..212] K,) (NNP:[213..218] Inoue) (NNP:[219..220] T)
        (,:[220..221] ,) (NNP:[223..231] Ishikawa) (NNP:[232..234] T.)))

;section 3 Span:238..311
;Department of Pathology, Faculty of Medicine, University of Tokyo, Japan.
(SEC
  (FRAG (NNP:[238..248] Department) (IN:[249..251] of)
        (NNP:[252..261] Pathology) (,:[261..262] ,) (NNP:[263..270] Faculty)
        (IN:[271..273] of) (NNP:[274..282] Medicine) (,:[282..283] ,)
        (NNP:[284..294] University) (IN:[295..297] of) (NNP:[298..303] Tokyo)
        (,:[303..304] ,) (NNP:[305..310] Japan) (.:[310..311] .)))

;sentence 4 Span:315..453
;We performed molecular biological studies as well as immunohistochemical 
;analysis of three cases of giant cell carcinoma of the pancreas.
;[416..452]:malignancy-type:"giant cell carcinoma of the pancreas"
(SENT
  (S
    (NP-SBJ (PRP:[315..317] We))
    (VP (VBD:[318..327] performed)
      (NP
        (NP
          (NP (JJ:[328..337] molecular) (JJ:[338..348] biological)
              (NNS:[349..356] studies))
          (CONJP (RB:[357..359] as) (RB:[360..364] well) (IN:[365..367] as))
          (NP (JJ:[368..387] immunohistochemical) (NN:[389..397] analysis)))
        (PP (IN:[398..400] of)
          (NP
            (NP (CD:[401..406] three) (NNS:[407..412] cases))
            (PP (IN:[413..415] of)
              (NP
                (NP
                  (NML (JJ:[416..421] giant) (NN:[422..426] cell))
                  (NN:[427..436] carcinoma))
                (PP (IN:[437..439] of)
                  (NP (DT:[440..443] the) (NN:[444..452] pancreas)))))))))
    (.:[452..453] .)))

;sentence 5 Span:454..767
;Histologically,  one case was a pleomorphic giant cell carcinoma consisting
;of pleomorphic giant/  small cells and spindle cells, one an osteoclast-like
;giant cell tumor composed  of osteoclastoid giant cells and pleomorphic small
;cells, and one a pleomorphic  giant cell carcinoma with osteoclastoid giant
;cells.
;[498..518]:malignancy-type:"giant cell carcinoma"
;[607..623]:malignancy-type:"giant cell tumor"
;[715..735]:malignancy-type:"giant cell carcinoma"
(SENT
  (S
    (ADVP (RB:[454..468] Histologically))
    (,:[468..469] ,)
    (NP-SBJ (CD:[471..474] one) (NN:[475..479] case))
    (VP (VBD:[480..483] was)
      (NP-PRD
        (NP (DT:[484..485] a) (JJ:[486..497] pleomorphic)
          
          (NML (JJ:[498..503] giant) (NN:[504..508] cell))
          (NN:[509..518] carcinoma))
        (VP (VBG:[519..529] consisting)
          (PP (IN:[530..532] of)
            (NP
              (NP
                (NP
                  (NP (JJ:[533..544] pleomorphic) (NN:[545..550] giant)
                    (NML-1 (-NONE-:[550..550] *P*)))
                  (SYM:[550..551] /)
                  (NP (JJ:[553..558] small)
                    (NML-1 (NNS:[559..564] cells))))
                (CC:[565..568] and)
                (NP (NN:[569..576] spindle) (NNS:[577..582] cells)))
              (,:[582..583] ,)
              (NP
                (NP
                  (NP (CD:[584..587] one))
                  (NP
                    (NP (DT:[588..590] an)
                      (ADJP (NN:[591..601] osteoclast) (HYPH:[601..602] -)
                            (JJ:[602..606] like))
                      
                      (NML (JJ:[607..612] giant) (NN:[613..617] cell))
                      (NN:[618..623] tumor))
                    (VP (VBN:[624..632] composed)
                      (NP (-NONE-:[632..632] *))
                      (PP-CLR (IN:[634..636] of)
                        (NP
                          (NP (JJ:[637..650] osteoclastoid)
                              (JJ:[651..656] giant) (NNS:[657..662] cells))
                          (CC:[663..666] and)
                          (NP (JJ:[667..678] pleomorphic) (JJ:[679..684] small)
                              (NNS:[685..690] cells)))))))
                (,:[690..691] ,) (CC:[692..695] and)
                (NP
                  (NP (CD:[696..699] one))
                  (NP
                    (NP (DT:[700..701] a) (JJ:[702..713] pleomorphic)
                      
                      (NML (JJ:[715..720] giant) (NN:[721..725] cell))
                      (NN:[726..735] carcinoma))
                    (PP (IN:[736..740] with)
                      (NP (JJ:[741..754] osteoclastoid) (JJ:[755..760] giant)
                          (NNS:[761..766] cells)))))))))))
    (.:[766..767] .)))

;sentence 6 Span:768..919
;Immunohistochemically,  pleomorphic giant cells and small pleomorphic cells
;were positive for epithelial  and mesenchymal markers throughout the cases.
(SENT
  (S
    (ADVP (RB:[768..789] Immunohistochemically))
    (,:[789..790] ,)
    (NP-SBJ
      (NP (JJ:[792..803] pleomorphic) (JJ:[804..809] giant)
          (NNS:[810..815] cells))
      (CC:[816..819] and)
      (NP (JJ:[820..825] small) (JJ:[826..837] pleomorphic)
          (NNS:[838..843] cells)))
    (VP (VBD:[844..848] were)
      (ADJP-PRD (JJ:[849..857] positive)
        (PP (IN:[858..861] for)
          (NP
            (ADJP (JJ:[862..872] epithelial) (CC:[874..877] and)
                  (JJ:[878..889] mesenchymal))
            (NNS:[890..897] markers))))
      (PP (IN:[898..908] throughout)
        (NP (DT:[909..912] the) (NNS:[913..918] cases))))
    (.:[918..919] .)))

;sentence 7 Span:920..1031
;Osteoclastoid cells were strongly  positive for PG-M1 (CD68), but negative
;for lysozyme and epithelial markers.
;[968..973]:gene-protein:"PG-M1"
;[975..979]:gene-protein:"CD68"
;[999..1007]:gene-protein:"lysozyme"
(SENT
  (S
    (NP-SBJ (JJ:[920..933] Osteoclastoid) (NNS:[934..939] cells))
    (VP (VBD:[940..944] were)
      (ADJP-PRD
        (ADJP (RB:[945..953] strongly) (JJ:[955..963] positive)
          (PP (IN:[964..967] for)
            (NP (NN:[968..973] PG-M1)
              (PRN (-LRB-:[974..975] -LRB-)
                (NP (NN:[975..979] CD68))
                (-RRB-:[979..980] -RRB-)))))
        (,:[980..981] ,) (CC:[982..985] but)
        (ADJP (JJ:[986..994] negative)
          (PP (IN:[995..998] for)
            (NP
              (NP (NN:[999..1007] lysozyme))
              (CC:[1008..1011] and)
              (NP (JJ:[1012..1022] epithelial) (NNS:[1023..1030] markers)))))))
    (.:[1030..1031] .)))

;sentence 8 Span:1033..1126
;Pleomorphic spindle cells showed the same immunoreactivity as pleomorphic 
;giant/small cells.
(SENT
  (S
    (NP-SBJ (JJ:[1033..1044] Pleomorphic) (NN:[1045..1052] spindle)
            (NNS:[1053..1058] cells))
    (VP (VBD:[1059..1065] showed)
      (NP
        (NP (DT:[1066..1069] the) (JJ:[1070..1074] same)
            (NN:[1075..1091] immunoreactivity))
        (PP (IN:[1092..1094] as)
          (NP
            (NP
              (ADJP-1 (JJ:[1095..1106] pleomorphic))
              (JJ:[1108..1113] giant)
              (NML-2 (-NONE-:[1113..1113] *P*)))
            (SYM:[1113..1114] /)
            (NP
              (ADJP-1 (-NONE-:[1114..1114] *P*))
              (JJ:[1114..1119] small)
              (NML-2 (NNS:[1120..1125] cells)))))))
    (.:[1125..1126] .)))

;sentence 9 Span:1127..1303
;Genetically, all cases contained a mutation in the K-ras  (codons 12, 13)
;oncogene, but neither p53 (exons 5-8) nor p16INK4 (exons 1, 2)  gene
;mutations were found in any case.
;[1178..1183]:gene-rna:"K-ras"
;[1186..1195]:variation-location:"codons 12"
;[1186..1192]...[1197..1199]:variation-location:"codons"..."13"
;[1223..1226]:gene-rna:"p53"
;[1228..1237]:variation-location:"exons 5-8"
;[1243..1250]:gene-rna:"p16INK4"
;[1252..1259]:variation-location:"exons 1"
;[1252..1257]...[1261..1262]:variation-location:"exons"..."2"
;[1270..1279]:variation-event:"mutations"
(SENT
  (S
    (S
      (ADVP (RB:[1127..1138] Genetically))
      (,:[1138..1139] ,)
      (NP-SBJ (DT:[1140..1143] all) (NNS:[1144..1149] cases))
      (VP (VBD:[1150..1159] contained)
        (NP
          (NP (DT:[1160..1161] a) (NN:[1162..1170] mutation))
          (PP (IN:[1171..1173] in)
            (NP (DT:[1174..1177] the) (NN:[1178..1183] K-ras)
              (PRN (-LRB-:[1185..1186] -LRB-)
                (NP
                  (NP
                    (NML-1 (NNS:[1186..1192] codons))
                    (CD:[1193..1195] 12))
                  (,:[1195..1196] ,)
                  (NP
                    (NML-1 (-NONE-:[1196..1196] *P*))
                    (CD:[1197..1199] 13)))
                (-RRB-:[1199..1200] -RRB-))
              (NN:[1201..1209] oncogene))))))
    (,:[1209..1210] ,) (CC:[1211..1214] but)
    (S
      (NP-SBJ-2 (CC:[1215..1222] neither)
        (NP (NN:[1223..1226] p53)
          (PRN (-LRB-:[1227..1228] -LRB-)
            (NP
              (NP (NNS:[1228..1233] exons) (CD:[1234..1235] 5))
              (PP (HYPH:[1235..1236] -)
                (NP (CD:[1236..1237] 8)))))
          (-RRB-:[1237..1238] -RRB-)
          (NML-3 (-NONE-:[1238..1238] *P*)))
        (CC:[1239..1242] nor)
        (NP (NN:[1243..1250] p16INK4)
          (PRN (-LRB-:[1251..1252] -LRB-)
            (NP
              (NP
                (NML-4 (NNS:[1252..1257] exons))
                (CD:[1258..1259] 1))
              (,:[1259..1260] ,)
              (NP
                (NML-4 (-NONE-:[1260..1260] *P*))
                (CD:[1261..1262] 2)))
            (-RRB-:[1262..1263] -RRB-))
          (NML-3 (NN:[1265..1269] gene) (NNS:[1270..1279] mutations))))
      (VP (VBD:[1280..1284] were)
        (VP (VBN:[1285..1290] found)
          (NP-2 (-NONE-:[1290..1290] *))
          (PP (IN:[1291..1293] in)
            (NP (DT:[1294..1297] any) (NN:[1298..1302] case))))))
    (.:[1302..1303] .)))

;sentence 10 Span:1304..1426
;Furthermore, Loss of heterozygosity (LOH)  of the p53, p161NK4. APC, and DPC4
;gene loci was not found in any of the cases.
;[1317..1339]:variation-type:"Loss of heterozygosity"
;[1341..1344]:variation-type:"LOH"
;[1354..1357]:gene-rna:"p53"
;[1359..1366]:gene-rna:"p161NK4"
;[1368..1371]:gene-rna:"APC"
;[1377..1381]:gene-rna:"DPC4"
(SENT
  (S
    (ADVP (RB:[1304..1315] Furthermore))
    (,:[1315..1316] ,)
    (NP-SBJ-2
      (NP
        (NP (NN:[1317..1321] Loss))
        (PP (IN:[1322..1324] of)
          (NP (NN:[1325..1339] heterozygosity))))
      (NP (-LRB-:[1340..1341] -LRB-) (NN:[1341..1344] LOH)
          (-RRB-:[1344..1345] -RRB-))
      (PP (IN:[1347..1349] of)
        (NP
          (NP (DT:[1350..1353] the) (NN:[1354..1357] p53)
            (NML-1 (-NONE-:[1357..1357] *P*)))
          (,:[1357..1358] ,)
          (NP (NN:[1359..1366] p161NK4) (.:[1366..1367] .) (NN:[1368..1371] APC)
            (NML-1 (-NONE-:[1371..1371] *P*)))
          (,:[1371..1372] ,) (CC:[1373..1376] and)
          (NP (NN:[1377..1381] DPC4)
            (NML-1 (NN:[1382..1386] gene) (NNS:[1387..1391] loci))))))
    (VP (VBD:[1392..1395] was) (RB:[1396..1399] not)
      (VP (VBN:[1400..1405] found)
        (NP-2 (-NONE-:[1405..1405] *))
        (PP (IN:[1406..1408] in)
          (NP
            (NP (DT:[1409..1412] any))
            (PP (IN:[1413..1415] of)
              (NP (DT:[1416..1419] the) (NNS:[1420..1425] cases)))))))
    (.:[1425..1426] .)))

;sentence 11 Span:1428..1539
;Immunohistochemical study demonstrated this tumor to be of epithelial origin 
;with mesenchymal differentiation.
(SENT
  (S
    (NP-SBJ (JJ:[1428..1447] Immunohistochemical) (NN:[1448..1453] study))
    (VP (VBD:[1454..1466] demonstrated)
      (S
        (NP-SBJ (DT:[1467..1471] this) (NN:[1472..1477] tumor))
        (VP (TO:[1478..1480] to)
          (VP (VB:[1481..1483] be)
            (PP-PRD (IN:[1484..1486] of)
              (NP (JJ:[1487..1497] epithelial) (NN:[1498..1504] origin)))
            (PP (IN:[1506..1510] with)
              (NP (JJ:[1511..1522] mesenchymal)
                  (NN:[1523..1538] differentiation)))))))
    (.:[1538..1539] .)))

;sentence 12 Span:1540..1672
;Genetically, initiation of the tumor is  similar to that of usual ductal
;adenocarcinoma, but progression might be rather  different.
;[1606..1627]:malignancy-type:"ductal adenocarcinoma"
(SENT
  (S
    (S
      (ADVP (RB:[1540..1551] Genetically))
      (,:[1551..1552] ,)
      (NP-SBJ
        (NP (NN:[1553..1563] initiation))
        (PP (IN:[1564..1566] of)
          (NP (DT:[1567..1570] the) (NN:[1571..1576] tumor))))
      (VP (VBZ:[1577..1579] is)
        (ADJP-PRD (JJ:[1581..1588] similar)
          (PP (TO:[1589..1591] to)
            (NP
              (NP (DT:[1592..1596] that))
              (PP (IN:[1597..1599] of)
                (NP (JJ:[1600..1605] usual)
                   (JJ:[1606..1612] ductal) (NN:[1613..1627] adenocarcinoma))))))))
    (,:[1627..1628] ,) (CC:[1629..1632] but)
    (S
      (NP-SBJ (NN:[1633..1644] progression))
      (VP (MD:[1645..1650] might)
        (VP (VB:[1651..1653] be)
          (ADJP-PRD (RB:[1654..1660] rather) (JJ:[1662..1671] different)))))
    (.:[1671..1672] .)))

;sentence 13 Span:1673..1791
;The peculiar histologic and biologic features of this tumor would be  the
;result of changes in other functional genes.
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1673..1676] The)
        (NML
          (NML
            (ADJP-2 (JJ:[1677..1685] peculiar))
            (JJ:[1686..1696] histologic)
            (NML-1 (-NONE-:[1696..1696] *P*)))
          (CC:[1697..1700] and)
          (NML
            (ADJP-2 (-NONE-:[1700..1700] *P*))
            (JJ:[1701..1709] biologic)
            (NML-1 (NNS:[1710..1718] features)))))
      (PP (IN:[1719..1721] of)
        (NP (DT:[1722..1726] this) (NN:[1727..1732] tumor))))
    (VP (MD:[1733..1738] would)
      (VP (VB:[1739..1741] be)
        (NP-PRD
          (NP (DT:[1743..1746] the) (NN:[1747..1753] result))
          (PP (IN:[1754..1756] of)
            (NP
              (NP (NNS:[1757..1764] changes))
              (PP (IN:[1765..1767] in)
                (NP (JJ:[1768..1773] other) (JJ:[1774..1784] functional)
                    (NNS:[1785..1790] genes))))))))
    (.:[1790..1791] .)))

;section 14 Span:1795..1840
;PMID: 10206490 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1795..1799] PMID) (::[1799..1800] :) (CD:[1801..1809] 10206490)
        (NN:[1810..1811] -LSB-) (NNP:[1811..1817] PubMed) (::[1818..1819] -)
        (NN:[1820..1827] indexed) (IN:[1828..1831] for)
        (NNP:[1832..1840] MEDLINE-RSB-)))
